Clinical Trials Logo

Stage IV Melanoma clinical trials

View clinical trials related to Stage IV Melanoma.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04356729 Recruiting - Stage IV Melanoma Clinical Trials

A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma

Start date: August 6, 2020
Phase: Phase 2
Study type: Interventional

This research study is studying a combination of two drugs that change the immune system and tumor as a possible treatment for metastatic or unresectable stage III or IV cutaneous melanoma. The names of the study drugs involved in this study are: - Atezolizumab - Bevacizumab

NCT ID: NCT04142931 Recruiting - Clinical trials for Triple Negative Breast Cancer

Sequentional Immuno Apheresis Plasma Volume Escalation Cohort Study of Reduction of Soluble Tumor Necrosis Factor Receptors 1 and 2 (sTNFR1/2) With or Without Nivolumab in Patients With Inoperable or Metastatic Solid Tumors

Start date: February 24, 2020
Phase: Phase 1
Study type: Interventional

Sequential immune apheresis plasma volume escalation cohort study of reduction of soluble Tumor Necrosis Factors Receptors 1/2 (sTNFR1/2), with or without Nivolumab, in patients with inoperable or metastatic solid Tumors. This study evaluates Immunicom fs LW-02 device used with Spectra Optia apheresis system, aiming to answer two different study questions: - Safety, tolerability and effectiveness of the device. - Safety, tolerability and effectiveness of the device, employed as monotherapy, or combined with Nivolumab.

NCT ID: NCT03385486 Recruiting - Stage IV Melanoma Clinical Trials

Study of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors

Start date: June 2, 2019
Phase: Phase 1
Study type: Interventional

This is a study of transfusion of TBX-3400 in patients with stage III and IV melanoma resistant or refractory to Immune Checkpoint Inhibitors. The patient's own blood cells are exposed to a protein that has been shown in the laboratory to result in anti-tumor activity. The study hypothesis is that TBX-3400 cells will enhance anti-tumor activity and improve the body's immune response.

NCT ID: NCT01168050 Recruiting - Stage IV Melanoma Clinical Trials

Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas.

NILOMEL
Start date: July 2010
Phase: Phase 2
Study type: Interventional

NILOMEL is a phase II multicentric uncontrolled open national trial assessing the efficacy of Nilotinib in first or second line treatment of primary melanomas , stage III unresectable melanomas, or Stage IV melanomas with c-KIT mutation or amplification. The primary objective is overall response rate (partial and complete response) according to RECIST 1.1 criteria, assessed using CT-SCAN (stage IV melanoma) or MRI (unresectable melanoma) after 6 months therapy with Nilotinib 800 mg/d. Secondary objectives include: - Disease control rate (complete, partial response and stable disease) - Metabolic response - Tolerance NCI CTCAE Version 3.0 - Biomarkers associated to response and disease control.